相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Cardiovascular comorbidity in psoriasis - psoriatic inflammation is more than just skin deep
Katharina S. Kommoss et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)
Current developments and perspectives in psoriasis
Michael P. Schoen et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2023)
Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients
L. Mastorino et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)
Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real-life experience on 638 patients with psoriasis
Luca Mastorino et al.
EXPERIMENTAL DERMATOLOGY (2023)
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis
Iain B. McInnes et al.
ARTHRITIS & RHEUMATOLOGY (2022)
Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?
Luca Mastorino et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
Paolo Dapavo et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Therapy of psoriasis during pregnancy and breast-feeding
Galina Balakirski et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)
Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
Martina Kojanova et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Matteo Megna et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis
G. Avallone et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)
Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study
Tiago Torres et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
Zenas Z. N. Yiu et al.
JAMA DERMATOLOGY (2022)
Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis
I-Hsin Huang et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2022)
Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
T. Graier et al.
SCIENTIFIC REPORTS (2022)
Considerations for patients with psoriasis travelling under immunosuppression
Brigitte Stephan et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2021)
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi et al.
DERMATOLOGY AND THERAPY (2021)
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Tiago Torres et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)
Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan
Megumi Kishimoto et al.
JOURNAL OF DERMATOLOGY (2020)
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
Kristian Reich et al.
LANCET (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials
Peter Foley et al.
JAMA DERMATOLOGY (2018)
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)